Difference between revisions of "Jaeger M, et al. J. Clin. Oncol. (2004) cited as Ref 562 in DOI: 10.1038/s41392-020-0110-5 (Q9825)"
Jump to navigation
Jump to search
(Created claim: Publication Date (P100): 2004, #quickstatements; #temporary_batch_1590002823654) |
(Created claim: Page(s) (P105): 2504-2504, #quickstatements; #temporary_batch_1590074839150) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Property / Published In Name String | |||
| + | J. Clin. Oncol. | ||
| Property / Published In Name String: J. Clin. Oncol. / rank | |||
| + | Normal rank | ||
| Property / Volume | |||
| + | 22 | ||
| Property / Volume: 22 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study (English) | ||
| Property / title: Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 2504-2504 | ||
| Property / Page(s): 2504-2504 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Jaeger M, et al. J. Clin. Oncol. (2004) cited as Ref 562 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Jaeger M
0 references
2004
0 references
J. Clin. Oncol.
0 references
22
0 references
Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study (English)
0 references
2504-2504
0 references
